February 13, 2020

Robert J. Delaversano
Principal Accounting Officer
OncoSec Medical Inc
24 North Main Street
Pennington, NJ 08534

       Re: OncoSec Medical Inc
           Form 10-K for the fiscal year ended July 31, 2019
           Filed October 28, 2019
           Form 10-Q for the quarterly period ended October 31, 2019
           Filed December 13, 2019
           File No. 000-54318

Dear Mr. Delaversano:

      We have reviewed your filings and have the following comment. In our
comment, we
may ask you to provide us with information so we may better understand your
disclosure.

       Please respond to this comment within ten business days by providing the
requested
information or advise us as soon as possible when you will respond. If you do
not believe our
comment applies to your facts and circumstances, please tell us why in your
response.

       After reviewing your response to this comment, we may have additional
comments.

Form 10-Q for the Quarterly Period Ended October 31, 2019

Financial Statements
Notes to Financial Statements
Note 8 - Commitments and Contingencies
License Agreement and Services Agreement, page 23

1.    You disclose "Whether or not Closing occurs, but subject to certain
conditions on
      effectiveness described above, the Company (1) will grant CGP and its
affiliates an
      exclusive license to develop, manufacture, commercialize, or otherwise
exploit current
      and future products, including TAVO and the VLA in the Territory for
which CGP will
      pay the Company up to 20% royalties on the net sales of such products in
the Territory."
       Please disclose the royalty rate or a range that does not exceed a 10
point range. Also
      disclose the minimum royalty and termination provisions specified in the
agreement.
 Robert J. Delaversano
OncoSec Medical Inc
February 13, 2020
Page 2

        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

       You may contact Lisa Vanjoske at (202) 551-3614 or Daniel Gordon at
(202) 551-3486 if
you have questions regarding the comment.



FirstName LastNameRobert J. Delaversano                   Sincerely,
Comapany NameOncoSec Medical Inc
                                                          Division of
Corporation Finance
February 13, 2020 Page 2                                  Office of Life
Sciences
FirstName LastName